For research use only. Not for therapeutic Use.
Semzuvolimab(CAT: I040847) is an investigational monoclonal antibody designed to modulate immune responses by targeting PD-1, a key immune checkpoint receptor. By blocking PD-1 interactions, Semzuvolimab enhances T-cell activation, promoting anti-tumor immunity in cancer research. It is being explored for its potential in treating various malignancies, including solid tumors and hematologic cancers, either as monotherapy or in combination with other immunotherapies. With its high specificity and potent immune-stimulating properties, Semzuvolimab represents a promising candidate in oncology and immunotherapy research, contributing to the development of next-generation cancer treatments.
| CAS Number | 2409099-32-5 |
| Purity | ≥95% |
